Maternal use of SSRIs, SNRIs and NaSSAs: Practical recommendations during pregnancy and lactation

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 97, Issue 6, 2012, Pages

  Sie, S D ^a   Wennink, J M B ^b   Van Driel, J J ^b,c   Te Winkel, A G W ^d   Boer, K ^c   Casteelen, G ^c   Van Weissenbruch, M M ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Netherlands Pharmacovigilance Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGITATION; ARTICLE; BLOOD PLACENTA BARRIER; BREAST FEEDING; BREAST MILK; COGNITION; COGNITIVE DEVELOPMENT; CONGENITAL MALFORMATION; CONVULSION; DEPRESSION; DRUG METABOLISM; DRUG MILK LEVEL; ENZYME POLYMORPHISM; FEEDING DISORDER; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM SEPTUM DEFECT; HUMAN; HYPOGLYCEMIA; INSOMNIA; IRRITABILITY; LACTATION; LETHARGY; MATERNAL CARE; NAUSEA; PATHOLOGICAL CRYING; PERSISTENT PULMONARY HYPERTENSION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PUERPERAL DEPRESSION; SIDE EFFECT; SLEEP DISORDER; TACHYPNEA; TREMOR; WITHDRAWAL SYNDROME;

EID: 85027952730     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/archdischild-2011-214239     Document Type: Article

References (67)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105. (Pubitemid 37432885)
2. Burt VK, Stein K. Epidemiology of depression throughout the female life cycle. J Clin Psychiatry 2002;63(Suppl 7):9-15. (Pubitemid 34454034)
3. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004;103:698-709. (Pubitemid 40459031)
4. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004;49:726-35. (Pubitemid 40100521)
5. Gavin NI, Gaynes BN, Lohr KN, et al. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005;106:1071-83. (Pubitemid 41532916)
6. Marcus SM, Flynn HA, Blow FC, et al. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health (Larchmt) 2003;12:373-80. (Pubitemid 36701614)
7. Marcus SM. Depression during pregnancy: rates, risks and consequences - Motherisk Update 2008. Can J Clin Pharmacol 2009;16:e15-22.
8. Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009;23:493-509.
9. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499-507. (Pubitemid 43200344)
10. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898-906. (Pubitemid 44188483)
11. Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007;164:1206-13. (Pubitemid 47292409)
12. Wisner KL, Sit DK, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009;166:557-66.
13. Dimidjian S, Goodman S. Nonpharmacologic intervention and prevention strategies for depression during pregnancy and the postpartum. Clin Obstet Gynecol 2009;52:498-515.
14. Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res Part A Clin Mol Teratol 2010;88:94-100.
15. Ververs T, Kaasenbrood H, Visser G, et al. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006;62:863-70. (Pubitemid 44521435)
16. Bakker MK, Kölling P, van den Berg PB, et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a populationbased cohort study from The Netherlands. Br J Clin Pharmacol 2008;65:600-6. (Pubitemid 351365128)
17. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;114:703-13.
18. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11-28.
19. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-15. (Pubitemid 26338730)
20. Ericson A, Källén B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503-8. (Pubitemid 29446550)
21. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997;89:713-18. (Pubitemid 27184852)
22. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609-10. (Pubitemid 28110208)
23. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246-8. (Pubitemid 23120281)
24. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Reprod Toxicol 2005;20:459.
25. Källén B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006;21:221-2. (Pubitemid 43294548)
26. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66:695-705.
27. Källén BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res Part A Clin Mol Teratol 2007;79:301-8. (Pubitemid 46980405)
28. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-33.
29. Bérard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80:18-27.
30. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1075-85. (Pubitemid 350020060)
31. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008;165:749-52. (Pubitemid 351810544)
32. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106:1289-96. (Pubitemid 41668948)
33. Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68-76. (Pubitemid 351317794)
34. Wogelius P, Nørgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701-4. (Pubitemid 44655607)
35. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
36. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotoninreuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-92. (Pubitemid 47001036)
37. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83. (Pubitemid 47001035)
38. Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010;2:29-36.
39. GlaxoSmithKline. Bupropion and Paroxetine (Study No. EPIP083). GlaxoSmithKline, UK, 2005.
40. Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006;67:1280-4. (Pubitemid 44439703)
41. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-30. (Pubitemid 32923672)
42. Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009;84:23-7.
43. Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol 2008;28:334-9.
44. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-83. (Pubitemid 40676760)
45. Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004;65:230-7.
46. Herbst F, Gortner L. [Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy?]. Z Geburtshilfe Neonatol 2003;207:232-4. (Pubitemid 38091016)
47. Pakalapati RK, Bolisetty S, Austin M P, et al. Neonatal seizures from in utero venlafaxine exposure. J Paediatr Child Health 2006;42:737-8. (Pubitemid 44581631)
48. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173-6. (Pubitemid 43213863)
49. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-32. (Pubitemid 36343460)
50. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312-16. (Pubitemid 38451555)
51. Van Driel JJ, Wennink JMB, Heres MH, et al. Intrauterine exposure to SSRIs: no reason for routine hypoglycaemia screening. Ned Tijdschr Geneeskd 2010;154:A339.
52. Oberlander TF, Papsdorf M, Brain UM, et al. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch Pediatr Adolesc Med 2010;164:444-51.
53. Finnegan L P, Connaughton JF Jr, Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2:141-58.
54. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotoninreuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87. (Pubitemid 43209105)
55. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009;18:246-52.
56. Hernández-Díaz S, Van Marter LJ, Werler MM, et al. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007;120:e272-82. (Pubitemid 47219476)
57. Wilson KL, Zelig CM, Harvey JP, et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011;28:19-24.
58. Tuccori M, Testi A, Antonioli L, et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 2009;31:1426-53.
59. Gentile S. SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 2005;19:623-33. (Pubitemid 41058372)
60. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007;161:22-9. (Pubitemid 46045459)
61. Klinger G, Frankenthal D, Merlob P, et al. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol 2011;31:615-20.
62. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005;28:137-52. (Pubitemid 40321769)
63. Gentile S, Rossi A, Bellantuono C. SSRIs during breastfeeding: spotlight on milkto-plasma ratio. Arch Womens Ment Health 2007;10:39-51. (Pubitemid 46536854)
64. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry 2004;161:1066-78. (Pubitemid 38735993)
65. Lattimore KA, Donn SM, Kaciroti N, et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a metaanalysis. J Perinatol 2005;25:595-604. (Pubitemid 43118131)
66. Lanza di Scalea T, Wisner KL. Antidepressant medication use during breastfeeding. Clin Obstet Gynecol 2009;52:483-97.
67. Gentile S. Use of contemporary antidepressants during breastfeeding: a proposal for a specific safety index. Drug Saf 2007;30:107-21. (Pubitemid 46193062)